Pharma BD Deal Intelligence
BMS and Immatics expanded their strategic alliance to develop multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs using ACTallo gamma-delta T cells, plus added one additional autologous TCR-T target. Immatics received $60M upfront ($80M total including autologous expansion) plus up to $700M in per-program milestones and royalties. UPDATE (terminated): On portfolio-prioritization grounds, Bristol Myers Squibb terminated this June-2022 ACTallo allogeneic collaboration (along with a related May-2023 opt-in), with the termination effective March 12, 2025. Immatics regained the rights, retained the upfront payments, and recognized accelerated deferred revenue; the companies' separate 2019 strategic collaboration remains ongoing. (BMS had separately terminated the distinct Dec-2021 IMA401 deal effective December 12, 2024.)